Companies › Bellicum Pharmaceuticals
2 active drug programs in 7 registered trials: 7 Phase 1; Oncology; next expected readout Oct 2032.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BPX-501 T cells (rivogenlecleucel) T cells transduced with CaspaCIDe safety switch (inducible caspase-9) | CASP9 | Phase 1 | Acute Lymphoblastic Leukemia; Leukemia; Hematologic Malignancy | Oct 2032 |
| rimiducid (AP1903) Dimerizer drug that activates iCasp9 suicide switch to eliminate BPX-501 cells in case of | – | Phase 1 | Acute Lymphoblastic Leukemia; Leukemia; Hematologic Malignancy | Oct 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01744223 | BPX-501 T cells (rivogenlecleucel) | Phase 1 | Acute Lymphoblastic Leukemia | Oncology | Oct 2032 |
| NCT01744223 | rimiducid (AP1903) | Phase 1 | Acute Lymphoblastic Leukemia | Oncology | Oct 2032 |
| NCT02477878 | BPX-501 T cells (rivogenlecleucel) | Phase 1 | Leukemia | Oncology | Jan 2033 |
| NCT02477878 | rimiducid (AP1903) | Phase 1 | Leukemia | Oncology | Jan 2033 |
| NCT03301168 | BPX-501 T cells (rivogenlecleucel) | Phase 1 | Acute Lymphoblastic Leukemia | Oncology | May 2034 |
| NCT03459170 | BPX-501 T cells (rivogenlecleucel) | Phase 1 | Hematologic Malignancy | Oncology | Sep 2035 |
| NCT03459170 | rimiducid (AP1903) | Phase 1 | Hematologic Malignancy | Oncology | Sep 2035 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.